Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;23(1):19-26.

Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children

Peiravian Farah  1 , Amirghofran Ahmad-Ali, Ghamsari Hanane, Emaminia Abbas
Affiliations

Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children

Peiravian Farah et al. Iran J Pediatr. 2013 Feb.

Abstract

Objective: Control of residual pulmonary arterial hypertension (PAH) after closure of left to right shunts in children is still a challenging issue. The purpose of this study was to compare the effect of two phosphodiesterase inhibitors in pediatric cardiac surgical patients.

Methods: A total of 48 postoperative children were enrolled in the study between 2008 and 2010. Patients were stratified based upon choice of pulmonary vasodilator into three equal groups (n = 16); Milrinone group received intravenous milrinone (0.75 µ/kg/min), Sildenafil group received oral sildenafil (0.3 mg/kg every 3 hours) and the Combination group received both medications.

Findings: Demographic variables and types of congenital anomalies were not different among the 3 groups. Patients in the Combination group had higher preoperative pulmonary artery to aortic (PA/AO) pressure ratios compared to other two groups (P=0.001). Postoperatively, patients in Milrinone group incurred lower systolic PA and PA/AO pressures compared to Sildenafil group (P=0.014, 0.003), but it was the same in Sildenafil and Combination group (P=0.2; 0.330 respectively). Pulmonary hypertensive crisis was noted in 6 patients in Sildenafil group, and 3 patients in Combination group (P=0.02). Significant rise in PA pressure was noticed after discontinuation of drug in Milrinone group (P=0.001), which was not observed in the Combination group (P= 0.6). No mortality was noticed in any of the groups.

Conclusion: Intravenous milrinone is more effective than oral sildenafil in control of postoperative PAH and elimination of pulmonary hypertensive crisis. Combination of two drugs reduces the risk of rebound pulmonary arterial hypertension after discontinuation of milrinone.

Keywords: Cardiac surgery; Children; Phosphodiesterase Inhibitors; Pulmonary arterial hypertension.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Systolic pulmonary artery pressure in 3 groups in the first 24 hours after surgery
Fig. 2
Fig. 2
Systolic pulmonary artery to aortic pressure in 3 groups in the first 24 hours after surgery
See this image and copyright information in PMC

References

    1. Schulze-Neick I, Hartenstein P, Li J, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation. 2003;108(Suppl I):167–73. - PubMed
    1. Leibovitch L, Matok I, Paret G. Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. Drugs. 2007;67(1):57–73. - PubMed
    1. Croom KF, Curran MP. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs. 2008;68(3):383–97. - PubMed
    1. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil use in pulmonary arterial hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57. - PubMed
    1. Peiravian F, Amirghofran AA, Borzouee M, et al. Oral sildenafil to control pulmonary hypertension after congenital heart surgery. Asian Cardiovasc Thorac Ann. 2007;15(2):113–7. - PubMed

LinkOut - more resources